A recent Phase II clinical trial reported that the mGlu5 negative allosteric modulator basimglurant did not significantly reduce clinician-rated symptoms of MDD in a large sample of individuals without recent alcohol abuse. The gene discussed is GRM5; the disease is major depressive disorder.